Unknown

Dataset Information

0

A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

ABSTRACT:

SUBMITTER: Maddocks K 

PROVIDER: S-EPMC5455147 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Maddocks Kami K   Hertlein Erin E   Chen Timothy L TL   Wagner Amy J AJ   Ling Yonghua Y   Flynn Joseph J   Phelps Mitch M   Johnson Amy J AJ   Byrd John C JC   Jones Jeffrey A JA  

Leukemia & lymphoma 20160114 9

Similar Datasets

Unknown 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.
| S-EPMC2904580 | biostudies-literature
Unknown A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors.
| S-EPMC3060938 | biostudies-literature
Unknown HSP90 inhibitor 17-DMAG exerts anticancer effects against gastric cancer cells principally by altering oxidant-antioxidant balance.
| S-EPMC5593576 | biostudies-literature
Unknown 17-DMAG dually inhibits Hsp90 and histone lysine demethylases in alveolar rhabdomyosarcoma.
| S-EPMC7811140 | biostudies-literature
Unknown Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
| S-EPMC7216400 | biostudies-literature
Unknown Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.
| S-EPMC4835239 | biostudies-literature
Unknown Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
| S-EPMC12904240 | biostudies-literature
Unknown Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.
| S-EPMC10447591 | biostudies-literature
Unknown HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line.
| S-EPMC7564044 | biostudies-literature
Unknown Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma.
| S-EPMC2761355 | biostudies-literature